VIRGINIA COMMONWEALTH UNIVERSITY

TASK ORDER TO FUND THE BASE YEAR OF THE NATION TRAINING AND DATA CENTER CONTRACT TO PROVIDE TECHNICAL ASSISTANCE, TRAINING, AND DATA SUPPORT TO WORK INCENTIVE PLANNING AND ASSISTANCE GRANT RECIPIENTS AND COMMUNITY PARTNERS

NATIONAL TRAINING AND DATA CENTER SUPPORT TO SUPPORT THE WORK INCENTIVE PLANNING AND ASSISTANCE (WIPA) PROGRAM. MODIFICATION TO DEOBLIGATE EXCESS FUNDING

WORK INCENTIVE PLANNING AND ASSISTANCE (WIPA) GRANT TECHNICAL ASSISTANCE AND TRAINING - MODIFICATION TO EXTEND ORDER FOR AND ADDITIONAL 2 WEEKS.

EOI::IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2026.

WORK INCENTIVE PLANNING AND ASSISTANCE (WIPA) GRANT TECHNICAL ASSISTANCE AND TRAINING - ORDER FOR 2 MONTHS OF SERVICES.

EOI::IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/09/2026. N01DA-24-8949

THIS TASK ORDER IS FOR TRAINING, TECHNICAL ASSISTANCE, AND DATA COLLECTION IN THE FOURTH YEAR OF CONTRACT 28321320D00060017 WITH VIRGINIA COMMONWEALTH UNIVERSITY NATIONAL TRAINING AND DATA CENTER. MODIFICATION TO DESCOPE AND REMOVE DEI LANGUAGE.

EOI::IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE::EOI THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION YEAR FOUR OF THE CONTRACT FOR A PERIOD OF PERFORMANCE OF JUNE 01, 2021 THROUGH MAY 31, 2022.

PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA; NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2026.

POP: 2/22/17-2/21/22. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

CONVERGENCE LAB INITIATIVE WHITE PAPER SUBMISSION

PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA; NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2025.

IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE

MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2024-7/9/2025. N01DA-24-8949

THIS TASK ORDER IS FOR TRAINING, TECHNICAL ASSISTANCE, AND DATA COLLECTION IN THE FOURTH YEAR OF CONTRACT 28321320D00060017 WITH VIRGINIA COMMONWEALTH UNIVERSITY NATIONAL TRAINING AND DATA CENTER

FABRICATION AND CHARACTERIZATION

MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2019-7/9/2024. N01DA-19-8949

POP: 2/22/17-2/21/22. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

TO DE-OBLIGATE FUNDS FROM FY2019 EXPIRING LINES IN ACCORDANCE WITH NIH OALM COMMUNICATION

EO 14042-THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION YEAR FOUR (4) OF THE CONTRACT FOR A PERIOD OF PERFORMANCE OF JUNE 01, 2021 THROUGH MAY 31, 2022.

PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA; NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2025.

CONVERGENCE LAB INITIATIVE (CLI)

IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE

VIRGINIA COMMONWEALTH UNIV:1109062 [23-003947]

THIS TASK ORDER IS FOR TRAINING, TECHNICAL ASSISTANCE, AND DATA COLLECTION IN THE THIRD YEAR OF CONTRACT 28321320D00060017 WITH VIRGINIA COMMONWEALTH UNIVERSITY NATIONAL TRAINING AND DATA CENTER

MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2019-7/9/2024. N01DA-19-8949

MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. POP 8/29/2014-7/9/2019. N01DA-14-8917.

FABRICATE AND CHARACTERIZE GDERNIAL POLYCRYSTALLINE MATERIALS FOR USE IN ADIABATIC DEMAGNETIZATION

THIS REQUISITION REQUESTS 1 UNIT OF CLIN 2042 ANALYZE CURRENT HELP LINE TRAINING MANUAL, MATERIALS, ASSESSMENTS, AND SCRIPTS.

THIS REQUISITION ORDERS 1 UNIT OF HELP LINE TRAINING FOR THE CURRENT CONTRACT YEAR.

POP: 2/22/17-2/21/22. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA; NIDA REF. NO. N01DA-22-8959. 02/22/2022 - 02/21/2024.

VIRGINIA COMMONWEALTH UNIV:1109062 [18-000033]

BAA: EVALUATION OF CURRENT APPROACHES USED TO ESTABLISH BIOEQUIVALENCE OF NASAL SPRAYS FOR LOCAL ACTION IN CHILDREN (PMQWP 253)

BROAD AGENCY ANNOUNCEMENT (BAA) EVALUATING RELATIONSHIPS BETWEEN IN VITRO NASAL SPRAY CHARACTERIZATION TEST METRICS FOR BIOEQUIVALENCE AND NASAL DEPOSITION IN SILICO AND IN VITRO

TO DE-OBLIGATE FUNDS FROM FY2018 EXPIRING LINES IN ACCORDANCE WITH NIH OALM COMMUNICATION 23-18

EO 14042-THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION YEAR FOUR (4) OF THE CONTRACT FOR A PERIOD OF PERFORMANCE OF JUNE 01, 2021 THROUGH MAY 31, 2022.

TECHNICAL ASSISTANCE AND TRAINING FOR THE WORK INCENTIVE PLANNING AND ASSISTANCE GRANTEES. MODIFICATION TO CORRECT DE-OBLIGATION IN PREVIOUS MOD.

POP: 2/22/17-2/21/22. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

GENOMIC RESEARCH ALLIANCE FOR TRANSPLANTATION (GRAFT)